The SWX Swiss Exchange has announced that Italy-based Newron Pharmaceuticals is to be included in the Swiss Performance Index with a free float of 100%.
The SWX has approved the firm's application and its listing will begin on May 6. Companies wth a primary listing on the SWX will be able to join the SPI as of May 1. The index currently covers roughly 240 companies.
The news follows an announcement that fellow Italian company Bioxell will be included in the SPI under the same terms and details.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze